The Effect of Statin Use on Mortality in Systemic Autoimmune Rheumatic Diseases

REFERENCES

1. 1.↵
   1. Prasad M,
   2. Hermann J,
   3. Gabriel SE,
   4. Weyand CM,
   5. Mulvagh S,
   6. Mankad R,
   7. et al.

   Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Rheumatol 2015;12:168–76.

   OpenUrl
2. 2.↵
   1. Bernatsky S,
   2. Linehan T,
   3. Hanly JG

   . The accuracy of administrative data diagnoses of systemic autoimmune rheumatic diseases. J Rheumatol 2011;38:1612–6.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Breunig M,
   2. Kleinert S,
   3. Lehmann S,
   4. Kneitz C,
   5. Feuchtenberger M,
   6. Tony HP,
   7. et al.

   Simple screening tools predict death and cardiovascular events in patients with rheumatic disease. Scand J Rheumatol 2018;47:102–9.

   OpenUrl
4. 4.↵
   1. Bartoloni E,
   2. Alunno A,
   3. Gerli R

   . Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases. Nat Rev Cardiol 2018;15:33–44.

   OpenUrl
5. 5.↵
   1. Bartoloni E,
   2. Shoenfeld Y,
   3. Gerli R

   . Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res 2011;63:178–83.

   OpenUrlCrossRef
6. 6.↵
   1. Alenghat FJ

   . The prevalence of atherosclerosis in those with inflammatory connective tissue disease by race, age, and traditional risk factors. Sci Rep 2016;6:20303.

   OpenUrl
7. 7.↵
   1. Aviña-Zubieta JA,
   2. To F,
   3. Vostretsova K,
   4. De Vera MA,
   5. Sayre EC,
   6. Esdaile JM

   . Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population-based study. Arthritis Care Res 2017;69:849–56.

   OpenUrl
8. 8.↵
   1. Schoenfeld S,
   2. Kasturi S,
   3. Costenbader K

   . The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 2013;43:77–95.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Urowitz M,
   2. Bookman A,
   3. Koehler B,
   4. Gordon D,
   5. Smythe H,
   6. Ogryzlo M

   . The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221–5.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Bartels CM,
    2. Buhr KA,
    3. Goldberg JW,
    4. Bell CL,
    5. Visekruna M,
    6. Nekkanti S,
    7. et al.

    Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol 2014;41:680–7.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Hak AE,
    2. Karlson EW,
    3. Feskanich D,
    4. Stampfer MJ,
    5. Costenbader KH

    . Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses’ health study. Arthritis Rheumatol 2009;61:1396–402.

    OpenUrl
12. 12.↵
    1. Lee Y,
    2. Choi S,
    3. Ji J,
    4. Song G

    . Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus 2016;25:727–34.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Jorge AM,
    2. Lu N,
    3. Rai SK,
    4. Zhang Y,
    5. Choi H

    . Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999–2014). Rheumatology 2018;57:337–44.

    OpenUrl
14. 14.↵
    1. Man A,
    2. Zhu Y,
    3. Zhang Y,
    4. Dubreuil M,
    5. Rho YH,
    6. Peloquin C,
    7. et al.

    The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study. Ann Rheum Dis 2013;72:1188–93.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Aviña-Zubieta JA,
    2. Mai A,
    3. Amiri N,
    4. Dehghan N,
    5. Ann Tan J,
    6. Sayre EC,
    7. et al.

    Risk of myocardial infarction and stroke in patients with granulomatosis with polyangiitis (Wegener’s): a population-based study. Arthritis Rheumatol 2016;68:2752–9.

    OpenUrl
16. 16.↵
    1. Tan JA,
    2. Dehghan N,
    3. Chen W,
    4. Xie H,
    5. Esdaile JM,
    6. Avina-Zubieta JA

    . Mortality in ANCA-associated vasculitis: a meta-analysis of observational studies. Ann Rheum Dis 2017;76:1566–74.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Rai SK,
    2. Choi HK,
    3. Sayre EC,
    4. Aviña-Zubieta JA

    . Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study. Rheumatology 2016;55:461–9.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Linos E,
    2. Fiorentino D,
    3. Lingala B,
    4. Krishnan E,
    5. Chung L

    . Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey. Arthritis Res Ther 2013;15:R7.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Dobloug GC,
    2. Svensson J,
    3. Lundberg IE,
    4. Holmqvist M

    . Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. Ann Rheum Dis 2018;77:40–7.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Taylor F,
    2. Huffman MD,
    3. Macedo AF,
    4. Moore TH,
    5. Burke M,
    6. Davey Smith G,
    7. et al.

    Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013:CD004816.
21. 21.↵
    1. Cholesterol Treatment Trialists’ (CTT) Collaborators,
    2. Mihaylova B,
    3. Emberson J,
    4. Blackwell L,
    5. Keech A,
    6. Simes J,
    7. Barnes EH,
    8. et al.

    The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581–90.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Blak BT,
    2. Thompson M,
    3. Dattani H,
    4. Bourke A

    . Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011;19:251–5.

    OpenUrlPubMed
23. 23.↵
    NHS Digital. Read Codes. [Internet. Accessed June 11, 2018.] Available from: digital.nhs.uk/article/1104/Read-Codes
24. 24.↵
    1. FDB

    . Multilex. [Internet. Accessed June 11, 2018.] Available from: www.fdbhealth.co.uk/solutions/multilex
25. 25.↵
    1. Armstrong SM,
    2. Wither JE,
    3. Borowoy AM,
    4. Landolt-Marticorena C,
    5. Davis AM,
    6. Johnson SR

    . Development, sensibility, and validity of a systemic autoimmune rheumatic disease case ascertainment tool. J Rheumatol 2017;44:18–23.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Gonzalez-Gay MA,
    2. Pina T

    . Giant cell arteritis and polymyalgia rheumatica: an update. Curr Rheumatol Rep 2015;17:6.

    OpenUrl
27. 27.↵
    1. Herrett E,
    2. Thomas SL,
    3. Schoonen WM,
    4. Smeeth L,
    5. Hall AJ

    . Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4–14.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. D’Agostino RB,
    2. Rubin DB

    . Estimating and using propensity scores with partially missing data. J Am Stat Assoc 2000;95:749–59.

    OpenUrlCrossRef
29. 29.↵
    1. Austin PC

    . A comparison of 12 algorithms for matching on the propensity score. Stat Med 2014;33:1057–69.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Seeger JD,
    2. Walker AM,
    3. Williams PL,
    4. Saperia GM,
    5. Sacks FM

    . A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol 2003;92:1447–51.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Mihos CG,
    2. Artola RT,
    3. Santana O

    . The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review. Rheumatol Int 2012;32:287–94.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Greenwood J,
    2. Steinman L,
    3. Zamvil SS

    . Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006;6:358–70.

    OpenUrlCrossRefPubMed
33. 33.↵
    1. Sahebkar A,
    2. Rathouska J,
    3. Derosa G,
    4. Maffioli P,
    5. Nachtigal P

    . Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: a systematic review and meta-analysis of controlled trials. Autoimmun Rev 2016;15:344–53.

    OpenUrl
34. 34.↵
    1. Ridker PM,
    2. MacFadyen J,
    3. Libby P,
    4. Glynn RJ

    . Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol 2010;106:204–9.

    OpenUrlCrossRefPubMed
35. 35.↵
    1. Kuwana M

    . Potential benefit of statins for vascular disease in systemic sclerosis. Curr Opin Rheumatol 2006;18:594–600.

    OpenUrlPubMed
36. 36.↵
    1. Al-Ani B

    . Simvastatin inhibits neutrophil degranulation induced by anti-neutrophil cytoplasm auto-antibodies and N-formylmethionine-leucine-phenylalanine (fMLP) peptide. Saudi Med J 2013;34:477–83.

    OpenUrlPubMed
37. 37.↵
    1. Bernatsky S,
    2. Boivin JF,
    3. Joseph L,
    4. Manzi S,
    5. Ginzler E,
    6. Gladman DD,
    7. et al.

    Mortality in systemic lupus erythematosus. Arthritis Rheumatol 2006;54:2550–7.

    OpenUrl
38. 38.↵
    1. Keller SF,
    2. Miloslavsky EM

    . Corticosteroids in antineutrophil cytoplasmic antibody-associated vasculitis. Rheum Dis Clin North Am 2016;42:91–101.

    OpenUrl
39. 39.↵
    1. Apostolopoulos D,
    2. Morand EF

    . It hasn’t gone away: the problem of glucocorticoid use in lupus remains. Rheumatology 2017;56:i114–22.

    OpenUrl
40. 40.↵
    1. Pinto AJ,
    2. Roschel H,
    3. de Sá Pinto AL,
    4. Lima FR,
    5. Pereira RMR,
    6. Silva CA,
    7. et al.

    Physical inactivity and sedentary behavior: Overlooked risk factors in autoimmune rheumatic diseases? Autoimmun Rev 2017;16:667–74.

    OpenUrl
41. 41.↵
    1. Artola RT,
    2. Mihos CG,
    3. Santana O

    . Effects of statin therapy in patients with systemic lupus erythematosus. South Med J 2016;109:705–11.

    OpenUrl
42. 42.↵
    1. Andrades C,
    2. Fuego C,
    3. Manrique-Arija S,
    4. Fernandez-Nebro A

    . Management of cardiovascular risk in systemic lupus erythematosus: a systematic review. Lupus 2017;26:1407–19.

    OpenUrl
43. 43.↵
    1. Petri MA,
    2. Kiani AN,
    3. Post W,
    4. Christopher-Stine L,
    5. Magder LS

    . Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011;70:760–5.

    OpenUrlAbstract/FREE Full Text
44. 44.↵
    1. Mok CC,
    2. Wong CK,
    3. To CH,
    4. Lai JP,
    5. Lam CS

    . Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res 2011;63:875–83.

    OpenUrlCrossRef
45. 45.↵
    1. Schanberg LE,
    2. Sandborg C,
    3. Barnhart HX,
    4. Ardoin SP,
    5. Yow E,
    6. Evans GW,
    7. et al;
    8. Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators

    . Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheumatol 2012;64:285–96.

    OpenUrl
46. 46.↵
    1. Plazak W,
    2. Gryga K,
    3. Dziedzic H,
    4. Tomkiewicz-Pajak L,
    5. Konieczynska M,
    6. Podolec P,
    7. et al.

    Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study. Arthritis Res Ther 2011;13:R117.

    OpenUrlCrossRefPubMed
47. 47.↵
    1. Yu HH,
    2. Chen PC,
    3. Yang YH,
    4. Wang LC,
    5. Lee JH,
    6. Lin YT,
    7. et al.

    Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study. Atherosclerosis 2015;243:11–8.

    OpenUrl
48. 48.↵
    1. Ray WA

    . Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915–20.

    OpenUrlCrossRefPubMed
49. 49.↵
    1. Levesque LE,
    2. Hanley JA,
    3. Kezouh A,
    4. Suissa S

    . Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010;340:b5087.

    OpenUrlFREE Full Text